Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|The Lancet Oncology|2011Cited by 4.1k
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLCShugeng Gao, Jie He, Ning Li et al.|Journal of Thoracic Oncology|2020Cited by 415
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu et al.|Journal of Clinical Oncology|2023Cited by 386
Hypoxia‐inducible factor‐1α and nuclear factor‐κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non‐small‐cell lung cancer cellsRong Guo, Jie Wang|Cancer Science|2019Cited by 56
Multi-omics profiling of primary small cell carcinoma of the esophagus reveals RB1 disruption and additional molecular subtypesRenda Li, Jie He, Sijin Sun et al.|Nature Communications|2021Cited by 50